insulin glargine vs insulin icodec

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Type 2 Diabetes

Shared mechanism: Insulin receptor (basal) · full Type 2 Diabetes pipeline

insulin glargine · Lantus

Marketed by Sanofi

Approved in Type 2 Diabetespeptide
Partial signal

NCT00069784 · Phase 3 · completed

The trial randomized 12,537 participants and used adjudicated clinical cardiovascular events, but treatment assignment was open-label rather than double-blinded. Neither primary cardiovascular endpoint was statistically significant in favor of insulin glargine, so the evidence supports a well-powered but inconclusive or negative finding rather than strong evidence of benefit.

Next expected readout: June 2027 · NCT07173712 (registry estimate)

No aligned efficacy figure on record for this race.

insulin icodec · Awiqli

Marketed by Novo Nordisk

Approved in Type 2 Diabetespeptide
Partial signal

NCT04760626 · Phase 3 · completed

The study was randomized and actively controlled, but it was open-label, with 542 participants assigned to insulin icodec and 543 to once-daily basal insulin analogues. The primary HbA1c endpoint was met for non-inferiority, but HbA1c is a surrogate measure rather than a hard clinical or endoscopic endpoint, supporting a moderate evidence grade.

Next expected readout: October 2027 · NCT07747402 (registry estimate)

Reported efficacy

Change in Glycated Haemoglobin (HbA1c) (Week 0, Week 26): Change in Glycated Haemoglobin (HbA1c) (Week 0, Week 26): Insulin Icodec -0.84 Percentage (%) point (Standard Deviation 0.83) vs Insulin Glargine -0.58 Percentage (%) point (Standard Deviation 0.89) (met)

Result source: NCT06340854

Results for Type 2 Diabetes

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointinsulin glargineinsulin icodec
HbA1c, change-0.6% vs -0.8%vs Insulin Icodecwk 26 · n 201NCT06340854
18 other results
  • -1.0% vs -1% wk 26 · n 361 · Phase 3 · primary NCT05462756
  • -1.0% vs -1% wk 26 · n 361 · Phase 3 · secondary NCT05462756
  • -1.7% vs -1.4% wk 26 · n 134 · Phase 4 · primary NCT00391027
  • -2.0% vs -1.8% wk 26 · n 154 · Phase 4 · primary NCT00418522
  • -1.7% vs -1.1% wk 24 · n 224 · Phase 4 · primary NCT00751114
  • -1.3% vs -1.4% wk 24 · n 30 · Phase 4 · primary NCT00686712
  • -1.9% vs -1.4% wk 24 · n 25 · Phase 4 · primary NCT00686712
  • -1.3% vs -1.4% wk 12 · n 46 · Phase 4 · primary NCT02455076
  • -1.1% vs -1.4% wk 12 · n 50 · Phase 4 · primary NCT02455076
  • -1.9% vs -1.7% wk 26 · n 203 · Phase 4 · secondary NCT00418522
  • -1.9% vs -1.8% wk 24 · n 467 · Phase 4 · secondary NCT01117350
  • -0.4% vs -0.1% wk 24 · n 49 · Phase 4 · secondary NCT00360698
  • -1.7% vs -1.5% wk 18 · n 134 · Phase 4 · secondary NCT00391027
  • -1.6% vs -1.3% wk 12 · n 134 · Phase 4 · secondary NCT00391027
  • -1.3% vs -1.1% wk 8 · n 134 · Phase 4 · secondary NCT00391027
  • -0.8% vs -0.6% wk 4 · n 134 · Phase 4 · secondary NCT00391027
  • -0.4% vs -0.3% wk 2 · n 134 · Phase 4 · secondary NCT00391027
  • -2.5% vs -2.1% wk 60 · n 144 · Phase 4 · secondary NCT00384085
-0.8% vs -0.6%vs Insulin Glarginewk 26 · n 204NCT06340854
11 other results
  • -1.6% vs -1.4% wk 26 · n 294 · Phase 3 · primary NCT04795531
  • -0.9% vs -0.7% wk 26 · n 263 · Phase 3 · primary NCT04770532
  • -1.2% vs -1.2% wk 26 · n 291 · Phase 3 · primary NCT04880850
  • -1.7% vs -1.3% wk 52 · n 542 · Phase 3 · primary NCT04760626
  • -1.6% vs -1.4% wk 52 · n 492 · Phase 3 · primary NCT04460885
  • -1.3% vs -1.1% wk 26 · n 122 · Phase 2 · primary NCT03751657
  • -0.5% vs -0.5% wk 16 · n 50 · Phase 2 · secondary NCT03922750
  • -0.8% vs -0.5% wk 16 · n 54 · Phase 2 · secondary NCT03922750
  • -1% vs -1.0% wk 16 · n 51 · Phase 2 · secondary NCT03951805
  • -1.2% vs -1.0% wk 16 · n 51 · Phase 2 · secondary NCT03951805
  • -1.4% vs -1.0% wk 16 · n 52 · Phase 2 · secondary NCT03951805
Body weight, change (kg)0.6 vs 2.0vs Insulin Icodecwk 26 · n 202NCT06340854
7 other results
  • 2.7 vs 2.5 wk 26 · n 365 · Phase 3 · secondary NCT05462756
  • 2.0 vs -3.0 wk 24 · n 474 · Phase 4 · secondary NCT01117350
  • 2.2 vs 1.1 wk 26 · n 125 · Phase 4 · secondary NCT00391027
  • 3.5 vs 2.3 wk 26 · n 203 · Phase 4 · secondary NCT00418522
  • 0.4 vs -1.1 wk 24 · n 227 · Phase 4 · secondary NCT00751114
  • 0.5 vs 0.2 wk 24 · n 48 · Phase 4 · secondary NCT00360698
  • -1 vs -0.5 n 42 · Phase 4 · secondary NCT02455076
2.0 vs 0.6vs Insulin Glarginewk 26 · n 204NCT06340854
10 other results
  • 2.8 vs 2.3 wk 26 · n 294 · Phase 3 · secondary NCT04795531
  • 1.4 vs -0.3 wk 26 · n 263 · Phase 3 · secondary NCT04770532
  • 2.7 vs 2.2 wk 26 · n 291 · Phase 3 · secondary NCT04880850
  • 2.3 vs 1.8 wk 52 · n 492 · Phase 3 · secondary NCT04460885
  • 1.5 vs 1.6 wk 26 · n 122 · Phase 2 · secondary NCT03751657
  • 1.3 vs 0.1 wk 16 · n 50 · Phase 2 · secondary NCT03922750
  • 0.6 vs 0.1 wk 16 · n 54 · Phase 2 · secondary NCT03922750
  • 0.9 vs 0.6 wk 16 · n 51 · Phase 2 · secondary NCT03951805
  • 1.1 vs 0.6 wk 16 · n 51 · Phase 2 · secondary NCT03951805
  • 1.3 vs 0.6 wk 16 · n 52 · Phase 2 · secondary NCT03951805
HbA1c below 7%48.4% vs 45.9%vs Liraglutidewk 24 · n 467NCT01117350
4 other results
  • 22.4% vs 8.8% wk 24 · n 49 · Phase 4 · primary NCT00360698
  • 51.1% vs 39.5% wk 60 · n 180 · Phase 4 · secondary NCT00384085
  • 62.6% vs 47.6% wk 26 · n 203 · Phase 4 · secondary NCT00418522
  • 67.9% vs 41.9% wk 24 · n 224 · Phase 4 · secondary NCT00751114
—Not posted · NCT05013229
Fasting plasma glucose, change-3.6 vs -2.1vs Liraglutidewk 24 · n 468NCT01117350
4 other results
  • -1.7 vs -3.3 wk 26 · n 134 · Phase 4 · secondary NCT00391027
  • -2.9 vs -3.0 wk 26 · n 203 · Phase 4 · secondary NCT00418522
  • -3.4 vs -1.1 wk 24 · n 214 · Phase 4 · secondary NCT00751114
  • -0.8 vs -0.8 wk 10 · n 154 · Phase 4 · secondary NCT01226043
-3.0 vs -3.0vs Insulin Degludecwk 26 · n 284NCT04795531
9 other results
  • -1.6 vs -1.6 wk 26 · n 260 · Phase 3 · secondary NCT04770532
  • -1.8 vs -1.6 wk 26 · n 283 · Phase 3 · secondary NCT04880850
  • -3.4 vs -3.3 wk 52 · n 480 · Phase 3 · secondary NCT04460885
  • -3.2 vs -3.0 wk 26 · n 121 · Phase 2 · secondary NCT03751657
  • -0.8 vs -0.6 wk 16 · n 50 · Phase 2 · secondary NCT03922750
  • -0.7 vs -0.6 wk 16 · n 52 · Phase 2 · secondary NCT03922750
  • -2.2 vs -2.3 wk 16 · n 51 · Phase 2 · secondary NCT03951805
  • -2.4 vs -2.3 wk 16 · n 50 · Phase 2 · secondary NCT03951805
  • -3.0 vs -2.3 wk 16 · n 51 · Phase 2 · secondary NCT03951805
3-point MACE (% with event)—Not posted · NCT00044447—Not posted · NCT05013229

HbA1c, change

insulin glargine
-0.6% vs -0.8%vs Insulin Icodecwk 26 · n 201NCT06340854
18 other results
  • -1.0% vs -1% wk 26 · n 361 · Phase 3 · primary NCT05462756
  • -1.0% vs -1% wk 26 · n 361 · Phase 3 · secondary NCT05462756
  • -1.7% vs -1.4% wk 26 · n 134 · Phase 4 · primary NCT00391027
  • -2.0% vs -1.8% wk 26 · n 154 · Phase 4 · primary NCT00418522
  • -1.7% vs -1.1% wk 24 · n 224 · Phase 4 · primary NCT00751114
  • -1.3% vs -1.4% wk 24 · n 30 · Phase 4 · primary NCT00686712
  • -1.9% vs -1.4% wk 24 · n 25 · Phase 4 · primary NCT00686712
  • -1.3% vs -1.4% wk 12 · n 46 · Phase 4 · primary NCT02455076
  • -1.1% vs -1.4% wk 12 · n 50 · Phase 4 · primary NCT02455076
  • -1.9% vs -1.7% wk 26 · n 203 · Phase 4 · secondary NCT00418522
  • -1.9% vs -1.8% wk 24 · n 467 · Phase 4 · secondary NCT01117350
  • -0.4% vs -0.1% wk 24 · n 49 · Phase 4 · secondary NCT00360698
  • -1.7% vs -1.5% wk 18 · n 134 · Phase 4 · secondary NCT00391027
  • -1.6% vs -1.3% wk 12 · n 134 · Phase 4 · secondary NCT00391027
  • -1.3% vs -1.1% wk 8 · n 134 · Phase 4 · secondary NCT00391027
  • -0.8% vs -0.6% wk 4 · n 134 · Phase 4 · secondary NCT00391027
  • -0.4% vs -0.3% wk 2 · n 134 · Phase 4 · secondary NCT00391027
  • -2.5% vs -2.1% wk 60 · n 144 · Phase 4 · secondary NCT00384085
insulin icodec
-0.8% vs -0.6%vs Insulin Glarginewk 26 · n 204NCT06340854
11 other results
  • -1.6% vs -1.4% wk 26 · n 294 · Phase 3 · primary NCT04795531
  • -0.9% vs -0.7% wk 26 · n 263 · Phase 3 · primary NCT04770532
  • -1.2% vs -1.2% wk 26 · n 291 · Phase 3 · primary NCT04880850
  • -1.7% vs -1.3% wk 52 · n 542 · Phase 3 · primary NCT04760626
  • -1.6% vs -1.4% wk 52 · n 492 · Phase 3 · primary NCT04460885
  • -1.3% vs -1.1% wk 26 · n 122 · Phase 2 · primary NCT03751657
  • -0.5% vs -0.5% wk 16 · n 50 · Phase 2 · secondary NCT03922750
  • -0.8% vs -0.5% wk 16 · n 54 · Phase 2 · secondary NCT03922750
  • -1% vs -1.0% wk 16 · n 51 · Phase 2 · secondary NCT03951805
  • -1.2% vs -1.0% wk 16 · n 51 · Phase 2 · secondary NCT03951805
  • -1.4% vs -1.0% wk 16 · n 52 · Phase 2 · secondary NCT03951805

Body weight, change (kg)

insulin glargine
0.6 vs 2.0vs Insulin Icodecwk 26 · n 202NCT06340854
7 other results
  • 2.7 vs 2.5 wk 26 · n 365 · Phase 3 · secondary NCT05462756
  • 2.0 vs -3.0 wk 24 · n 474 · Phase 4 · secondary NCT01117350
  • 2.2 vs 1.1 wk 26 · n 125 · Phase 4 · secondary NCT00391027
  • 3.5 vs 2.3 wk 26 · n 203 · Phase 4 · secondary NCT00418522
  • 0.4 vs -1.1 wk 24 · n 227 · Phase 4 · secondary NCT00751114
  • 0.5 vs 0.2 wk 24 · n 48 · Phase 4 · secondary NCT00360698
  • -1 vs -0.5 n 42 · Phase 4 · secondary NCT02455076
insulin icodec
2.0 vs 0.6vs Insulin Glarginewk 26 · n 204NCT06340854
10 other results
  • 2.8 vs 2.3 wk 26 · n 294 · Phase 3 · secondary NCT04795531
  • 1.4 vs -0.3 wk 26 · n 263 · Phase 3 · secondary NCT04770532
  • 2.7 vs 2.2 wk 26 · n 291 · Phase 3 · secondary NCT04880850
  • 2.3 vs 1.8 wk 52 · n 492 · Phase 3 · secondary NCT04460885
  • 1.5 vs 1.6 wk 26 · n 122 · Phase 2 · secondary NCT03751657
  • 1.3 vs 0.1 wk 16 · n 50 · Phase 2 · secondary NCT03922750
  • 0.6 vs 0.1 wk 16 · n 54 · Phase 2 · secondary NCT03922750
  • 0.9 vs 0.6 wk 16 · n 51 · Phase 2 · secondary NCT03951805
  • 1.1 vs 0.6 wk 16 · n 51 · Phase 2 · secondary NCT03951805
  • 1.3 vs 0.6 wk 16 · n 52 · Phase 2 · secondary NCT03951805

HbA1c below 7%

insulin glargine
48.4% vs 45.9%vs Liraglutidewk 24 · n 467NCT01117350
4 other results
  • 22.4% vs 8.8% wk 24 · n 49 · Phase 4 · primary NCT00360698
  • 51.1% vs 39.5% wk 60 · n 180 · Phase 4 · secondary NCT00384085
  • 62.6% vs 47.6% wk 26 · n 203 · Phase 4 · secondary NCT00418522
  • 67.9% vs 41.9% wk 24 · n 224 · Phase 4 · secondary NCT00751114
insulin icodec
—Not posted · NCT05013229

Fasting plasma glucose, change

insulin glargine
-3.6 vs -2.1vs Liraglutidewk 24 · n 468NCT01117350
4 other results
  • -1.7 vs -3.3 wk 26 · n 134 · Phase 4 · secondary NCT00391027
  • -2.9 vs -3.0 wk 26 · n 203 · Phase 4 · secondary NCT00418522
  • -3.4 vs -1.1 wk 24 · n 214 · Phase 4 · secondary NCT00751114
  • -0.8 vs -0.8 wk 10 · n 154 · Phase 4 · secondary NCT01226043
insulin icodec
-3.0 vs -3.0vs Insulin Degludecwk 26 · n 284NCT04795531
9 other results
  • -1.6 vs -1.6 wk 26 · n 260 · Phase 3 · secondary NCT04770532
  • -1.8 vs -1.6 wk 26 · n 283 · Phase 3 · secondary NCT04880850
  • -3.4 vs -3.3 wk 52 · n 480 · Phase 3 · secondary NCT04460885
  • -3.2 vs -3.0 wk 26 · n 121 · Phase 2 · secondary NCT03751657
  • -0.8 vs -0.6 wk 16 · n 50 · Phase 2 · secondary NCT03922750
  • -0.7 vs -0.6 wk 16 · n 52 · Phase 2 · secondary NCT03922750
  • -2.2 vs -2.3 wk 16 · n 51 · Phase 2 · secondary NCT03951805
  • -2.4 vs -2.3 wk 16 · n 50 · Phase 2 · secondary NCT03951805
  • -3.0 vs -2.3 wk 16 · n 51 · Phase 2 · secondary NCT03951805

3-point MACE (% with event)

insulin glargine
—Not posted · NCT00044447
insulin icodec
—Not posted · NCT05013229
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
6 other shared endpoints and safety

Coverage. insulin glargine: 10 of 10 rows · insulin icodec: 10 of 10 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricinsulin glargine
Rows use multiple source trials
insulin icodec
Rows use multiple source trials
HbA1c
absolute change · percentage points
No placebo or comparator arm
-1.19% (n=355) @ 52wka,b,c
NCT05662332 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3
show 3 more doses
-1.19% (n=355) @ 52wk
NCT05662332 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3
-1.16% (n=360) @ 52wk
NCT05662332 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3
-1.16% (n=360) @ 52wk
NCT05662332 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3
-1.23% (n=91) @ 52wkb,c
NCT05813912 · Phase 3 · registry result, not featured evidence · combination
Time Above Range
absolute value · percentage points
-11.19% (n=198) vs -20.54% (n=202) Insulin Icodec @ 26wkc
NCT06340854 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3
-20.54% (n=202) vs -11.19% (n=198) Insulin Glargine @ 26wkc
NCT06340854 · Phase 3 · combination · Type 2 Diabetes · phase 3
Time Above Range
absolute value · % of time
40.1 vs 41.6 Insulin Glargine % of time @ 26wkb,c
NCT05462756 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3
35.52 vs 39.71 Insulin Degludec % of time @ 26wkb,c
NCT04770532 · Phase 3
1 other source trial
30.47 vs 31.3 Insulin Glargine % of time @ 26wk
NCT04880850 · Phase 3
Time Below Range
absolute value · % of time
6.84 vs 5.25 Insulin Glargine % of time @ 26wkd,c,e
NCT05462756 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3
0.27 vs 0.21 Insulin Glargine % of time @ 52wkd,c,e
NCT04460885 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
Time in Range
absolute value · percentage points
11.04% (n=198) vs 19.94% (n=202) Insulin Icodec @ 26wkc
NCT06340854 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3
1 other source trial
58.39% (n=359) vs 57.05% (n=360) Insulin Glargine @ 26wk
NCT05462756 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3
19.94% (n=202) vs 11.04% (n=198) Insulin Glargine @ 26wkc
NCT06340854 · Phase 3 · combination · Type 2 Diabetes · phase 3
1 other source trial
63.13% (n=238) vs 59.5% (n=239) Insulin Degludec @ 26wk
NCT04770532 · Phase 3
Weight
absolute change · kg
No placebo or comparator arm
3.86 kg @ 52wka,b,c
NCT05662332 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3
show 1 more dose
3.29 kg @ 52wk
NCT05662332 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3
-3.85 kg @ 52wkb,c
NCT05813912 · Phase 3 · registry result, not featured evidence · combination
Dropout rate
19.3%f
NCT00069784 · Phase 3
show 29 more results
11.3%
NCT05114590 · Phase 4 · registry result, not featured evidence
28.3%
NCT04153981 · Phase 4 · registry result, not featured evidence
1.3%
NCT02561130 · Phase 4 · registry result, not featured evidence
8.5%Exenatide Inpatient
NCT02455076 · Phase 4 · registry result, not featured evidence
—Exenatide Outpatient
NCT02455076 · Phase 4 · registry result, not featured evidence
2%Exenatide Plus Glargine Insulin In
NCT02455076 · Phase 4 · registry result, not featured evidence · combination
—Comparative Period: Insulin Glargi
NCT01117350 · Phase 4 · registry result, not featured evidence
—Extension Period: Insulin Glargine
NCT01117350 · Phase 4 · registry result, not featured evidence
8.6%Insulin Glargine
NCT01117350 · Phase 4 · registry result, not featured evidence
—Crossover Phase: SoloSTAR® Pen
NCT01226043 · Phase 4 · registry result, not featured evidence
—Observational Phase: SoloSTAR® Pen
NCT01226043 · Phase 4 · registry result, not featured evidence
—Re-randomization Phase: SoloSTAR®
NCT01226043 · Phase 4 · registry result, not featured evidence
—SoloSTAR® Pen
NCT01226043 · Phase 4 · registry result, not featured evidence
15.2%
NCT00751114 · Phase 4 · registry result, not featured evidence
12.3%0.5 Units/kg
NCT00911625 · Phase 4 · registry result, not featured evidence
0%0.25 Units/kg
NCT00911625 · Phase 4 · registry result, not featured evidence
23.5%Lantus/Apidra-1
NCT00384085 · Phase 4 · registry result, not featured evidence · combination
20%Lantus/Apidra-3
NCT00384085 · Phase 4 · registry result, not featured evidence · combination
33.3%Insulin Glargine at Bedtime
NCT00686712 · Phase 4 · registry result, not featured evidence
44%Insulin Glargine in AM
NCT00686712 · Phase 4 · registry result, not featured evidence
—
NCT00360698 · Phase 4 · registry result, not featured evidence · combination
18.5%
NCT00391027 · Phase 4 · registry result, not featured evidence
37.9%
NCT00418522 · Phase 4 · registry result, not featured evidence
—
NCT00467649 · Phase 4 · registry result, not featured evidence · combination
1.5%
NCT06340854 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3
—Efsitora
NCT05662332 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3
—Glargine
NCT05662332 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3
9.3%Insulin Glargine
NCT05662332 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3
4.7%
NCT05462756 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3
8.3%g
NCT04760626 · Phase 3
show 14 more results
3.7%
NCT04460885 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
0%
NCT06340854 · Phase 3 · combination · Type 2 Diabetes · phase 3
2%
NCT04795531 · Phase 3
1.1%
NCT04770532 · Phase 3
5.5%
NCT04880850 · Phase 3
36.5%Insulin Icodec + Semaglutide
NCT05813912 · Phase 3 · registry result, not featured evidence · combination
—Insulin Icodec + Semaglutide: Trea
NCT05813912 · Phase 3 · registry result, not featured evidence · combination
2%
NCT05823948 · Phase 3 · registry result, not featured evidence
1.9%Insulin 287 (With 100% Loading Dos
NCT03922750 · Phase 2 · registry result, not featured evidence
0%Insulin 287 (Without Loading Dose)
NCT03922750 · Phase 2 · registry result, not featured evidence
2.4%
NCT03751657 · Phase 2 · registry result, not featured evidence
2%Insulin 287 (Titration Algorithm A
NCT03951805 · Phase 2 · registry result, not featured evidence
0%Insulin 287 (Titration Algorithm B
NCT03951805 · Phase 2 · registry result, not featured evidence
0%Insulin 287 (Titration Algorithm C
NCT03951805 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
1.7%f
NCT00069784 · Phase 3
show 29 more results
0.8%
NCT05114590 · Phase 4 · registry result, not featured evidence
—
NCT04153981 · Phase 4 · registry result, not featured evidence
—
NCT02561130 · Phase 4 · registry result, not featured evidence
6.4%Exenatide Inpatient
NCT02455076 · Phase 4 · registry result, not featured evidence
—Exenatide Outpatient
NCT02455076 · Phase 4 · registry result, not featured evidence
0%Exenatide Plus Glargine Insulin In
NCT02455076 · Phase 4 · registry result, not featured evidence · combination
—Comparative Period: Insulin Glargi
NCT01117350 · Phase 4 · registry result, not featured evidence
—Extension Period: Insulin Glargine
NCT01117350 · Phase 4 · registry result, not featured evidence
1.2%Insulin Glargine
NCT01117350 · Phase 4 · registry result, not featured evidence
—Crossover Phase: SoloSTAR® Pen
NCT01226043 · Phase 4 · registry result, not featured evidence
—Observational Phase: SoloSTAR® Pen
NCT01226043 · Phase 4 · registry result, not featured evidence
—Re-randomization Phase: SoloSTAR®
NCT01226043 · Phase 4 · registry result, not featured evidence
—SoloSTAR® Pen
NCT01226043 · Phase 4 · registry result, not featured evidence
0.8%
NCT00751114 · Phase 4 · registry result, not featured evidence
—0.5 Units/kg
NCT00911625 · Phase 4 · registry result, not featured evidence
—0.25 Units/kg
NCT00911625 · Phase 4 · registry result, not featured evidence
2.6%Lantus/Apidra-1
NCT00384085 · Phase 4 · registry result, not featured evidence · combination
2.6%Lantus/Apidra-3
NCT00384085 · Phase 4 · registry result, not featured evidence · combination
3.3%Insulin Glargine at Bedtime
NCT00686712 · Phase 4 · registry result, not featured evidence
4%Insulin Glargine in AM
NCT00686712 · Phase 4 · registry result, not featured evidence
—
NCT00360698 · Phase 4 · registry result, not featured evidence · combination
5.9%
NCT00391027 · Phase 4 · registry result, not featured evidence
3.2%
NCT00418522 · Phase 4 · registry result, not featured evidence
—
NCT00467649 · Phase 4 · registry result, not featured evidence · combination
—
NCT06340854 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3
—Efsitora
NCT05662332 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3
—Glargine
NCT05662332 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3
—Insulin Glargine
NCT05662332 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3
0.8%
NCT05462756 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3
—g
NCT04760626 · Phase 3
show 14 more results
—
NCT04460885 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
—
NCT06340854 · Phase 3 · combination · Type 2 Diabetes · phase 3
—
NCT04795531 · Phase 3
—
NCT04770532 · Phase 3
—
NCT04880850 · Phase 3
—Insulin Icodec + Semaglutide
NCT05813912 · Phase 3 · registry result, not featured evidence · combination
—Insulin Icodec + Semaglutide: Trea
NCT05813912 · Phase 3 · registry result, not featured evidence · combination
—
NCT05823948 · Phase 3 · registry result, not featured evidence
1.9%Insulin 287 (With 100% Loading Dos
NCT03922750 · Phase 2 · registry result, not featured evidence
0%Insulin 287 (Without Loading Dose)
NCT03922750 · Phase 2 · registry result, not featured evidence
—
NCT03751657 · Phase 2 · registry result, not featured evidence
2%Insulin 287 (Titration Algorithm A
NCT03951805 · Phase 2 · registry result, not featured evidence
0%Insulin 287 (Titration Algorithm B
NCT03951805 · Phase 2 · registry result, not featured evidence
0%Insulin 287 (Titration Algorithm C
NCT03951805 · Phase 2 · registry result, not featured evidence
Serious AEs
4.9%f
NCT00069784 · Phase 3
show 29 more results
0.8%
NCT05114590 · Phase 4 · registry result, not featured evidence
0.4%
NCT04153981 · Phase 4 · registry result, not featured evidence
3.9%
NCT02561130 · Phase 4 · registry result, not featured evidence
14.9%Exenatide Inpatient
NCT02455076 · Phase 4 · registry result, not featured evidence
22.9%Exenatide Outpatient
NCT02455076 · Phase 4 · registry result, not featured evidence
23.5%Exenatide Plus Glargine Insulin In
NCT02455076 · Phase 4 · registry result, not featured evidence · combination
2.3%Comparative Period: Insulin Glargi
NCT01117350 · Phase 4 · registry result, not featured evidence
3.1%Extension Period: Insulin Glargine
NCT01117350 · Phase 4 · registry result, not featured evidence
—Insulin Glargine
NCT01117350 · Phase 4 · registry result, not featured evidence
1%Crossover Phase: SoloSTAR® Pen
NCT01226043 · Phase 4 · registry result, not featured evidence
10.1%Observational Phase: SoloSTAR® Pen
NCT01226043 · Phase 4 · registry result, not featured evidence
0.6%Re-randomization Phase: SoloSTAR®
NCT01226043 · Phase 4 · registry result, not featured evidence
—SoloSTAR® Pen
NCT01226043 · Phase 4 · registry result, not featured evidence
6.3%
NCT00751114 · Phase 4 · registry result, not featured evidence
0%0.5 Units/kg
NCT00911625 · Phase 4 · registry result, not featured evidence
0%0.25 Units/kg
NCT00911625 · Phase 4 · registry result, not featured evidence
11.9%Lantus/Apidra-1
NCT00384085 · Phase 4 · registry result, not featured evidence · combination
11.3%Lantus/Apidra-3
NCT00384085 · Phase 4 · registry result, not featured evidence · combination
0%Insulin Glargine at Bedtime
NCT00686712 · Phase 4 · registry result, not featured evidence
4%Insulin Glargine in AM
NCT00686712 · Phase 4 · registry result, not featured evidence
2%
NCT00360698 · Phase 4 · registry result, not featured evidence · combination
5.9%
NCT00391027 · Phase 4 · registry result, not featured evidence
—
NCT00418522 · Phase 4 · registry result, not featured evidence
0%
NCT00467649 · Phase 4 · registry result, not featured evidence · combination
5.8%
NCT06340854 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3
6.5%Efsitora
NCT05662332 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3
5.3%Glargine
NCT05662332 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3
—Insulin Glargine
NCT05662332 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3
6.8%
NCT05462756 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3
8.3%g
NCT04760626 · Phase 3
show 14 more results
13%
NCT04460885 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
7.8%
NCT06340854 · Phase 3 · combination · Type 2 Diabetes · phase 3
5.1%
NCT04795531 · Phase 3
8.4%
NCT04770532 · Phase 3
7.6%
NCT04880850 · Phase 3
—Insulin Icodec + Semaglutide
NCT05813912 · Phase 3 · registry result, not featured evidence · combination
3.2%Insulin Icodec + Semaglutide: Trea
NCT05813912 · Phase 3 · registry result, not featured evidence · combination
3.9%
NCT05823948 · Phase 3 · registry result, not featured evidence
3.7%Insulin 287 (With 100% Loading Dos
NCT03922750 · Phase 2 · registry result, not featured evidence
0%Insulin 287 (Without Loading Dose)
NCT03922750 · Phase 2 · registry result, not featured evidence
1.6%
NCT03751657 · Phase 2 · registry result, not featured evidence
5.9%Insulin 287 (Titration Algorithm A
NCT03951805 · Phase 2 · registry result, not featured evidence
2%Insulin 287 (Titration Algorithm B
NCT03951805 · Phase 2 · registry result, not featured evidence
0%Insulin 287 (Titration Algorithm C
NCT03951805 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
f
hypoglycaemia 5.7%
upper respiratory tract infection 5.7%
NCT05114590 · Phase 4 · registry result, not featured evidence
show 22 more results
anaemia 1.9%
cough 0.4%
hyperglycaemia 0.4%
NCT04153981 · Phase 4 · registry result, not featured evidence
genitourinary infection 5.2%
abdominal pain 3.9%
injury 3.9%
NCT02561130 · Phase 4 · registry result, not featured evidence
nausea 10.6%
vomiting 2.1%
NCT02455076 · Phase 4 · registry result, not featured evidence
nausea 41.7%
vomiting 22.9%
NCT02455076 · Phase 4 · registry result, not featured evidence
nausea 9.8%
vomiting 5.9%
NCT02455076 · Phase 4 · registry result, not featured evidence · combination
nasopharyngitis 7.9%
headache 5%
diarrhoea 3.7%
NCT01117350 · Phase 4 · registry result, not featured evidence
nasopharyngitis 7.5%
diarrhoea 3.1%
headache 1.3%
NCT01117350 · Phase 4 · registry result, not featured evidence
upper respiratory tract infection 1.8%
nasopharyngitis 1.3%
sinusitis 1%
NCT01226043 · Phase 4 · registry result, not featured evidence
upper respiratory tract infection 8.8%
sinusitis 7.5%
oedema peripheral 5%
NCT01226043 · Phase 4 · registry result, not featured evidence
nasopharyngitis 3.6%
upper respiratory tract infection 2.4%
sinusitis 1.2%
NCT01226043 · Phase 4 · registry result, not featured evidence
headache 6.3%
influenza 3.4%
nasopharyngitis 3.4%
NCT00751114 · Phase 4 · registry result, not featured evidence
any infections and infestations 42.3%
any musculoskeletal and connective tissue disorders 22.7%
any gastrointestinal disorders 16.5%
NCT00384085 · Phase 4 · registry result, not featured evidence · combination
any infections and infestations 34%
any musculoskeletal and connective tissue disorders 23.2%
any nervous system disorders 20.1%
NCT00384085 · Phase 4 · registry result, not featured evidence · combination
symptomatic hypoglycemia 76.7%
asymptomatic retinal hemorrhage 3.3%
urinary tract infection 0%
NCT00686712 · Phase 4 · registry result, not featured evidence
symptomatic hypoglycemia 96%
asymptomatic retinal hemorrhage 0%
urinary tract infection 0%
NCT00686712 · Phase 4 · registry result, not featured evidence
hypoglycaemia 70.4%
nasopharyngitis 13.3%
cough 6.7%
NCT00391027 · Phase 4 · registry result, not featured evidence
hypoglycaemia 67.9%
tremor 31.6%
dizziness 18.9%
NCT00418522 · Phase 4 · registry result, not featured evidence
nausea 11.1%
diarrhoea 5.6%
hypertension 5.6%
NCT00467649 · Phase 4 · registry result, not featured evidence · combination
nasopharyngitis 7.8%
diabetic retinopathy 7.3%
diarrhoea 1.9%
NCT06340854 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3
influenza 7.3%
covid-19 5.3%
hypertension 5.3%
NCT05662332 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3
drug titration error 9.8%
urinary tract infection 6.3%
influenza 5.8%
NCT05662332 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3
nasopharyngitis 6.3%
influenza 3.8%
NCT05462756 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3
g
covid-19 7.9%
NCT04760626 · Phase 3
show 13 more results
covid-19 17.7%
back pain 8.1%
diarrhoea 7.9%
NCT04460885 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
nasopharyngitis 13.6%
diarrhoea 5.3%
diabetic retinopathy 2.9%
NCT06340854 · Phase 3 · combination · Type 2 Diabetes · phase 3
covid-19 8.2%
diabetic retinopathy 5.1%
influenza 5.1%
NCT04795531 · Phase 3
nasopharyngitis 8.4%
diarrhoea 5.3%
headache 5.3%
NCT04770532 · Phase 3
covid-19 8.6%
diarrhoea 5.2%
diabetic retinopathy 4.1%
NCT04880850 · Phase 3
nausea 19.1%
vomiting 8.5%
upper respiratory tract infection 7.4%
NCT05813912 · Phase 3 · registry result, not featured evidence · combination
nasopharyngitis 13.7%
covid-19 9.8%
back pain 7.8%
NCT05823948 · Phase 3 · registry result, not featured evidence
nasopharyngitis 14.8%
medical device site haemorrhage 9.3%
headache 5.6%
NCT03922750 · Phase 2 · registry result, not featured evidence
nasopharyngitis 14%
hypertension 6%
influenza 6%
NCT03922750 · Phase 2 · registry result, not featured evidence
headache 11.2%
nasopharyngitis 8%
upper respiratory tract infection 5.6%
NCT03751657 · Phase 2 · registry result, not featured evidence
back pain 9.8%
nasopharyngitis 9.8%
headache 0%
NCT03951805 · Phase 2 · registry result, not featured evidence
nasopharyngitis 13.7%
headache 5.9%
back pain 3.9%
NCT03951805 · Phase 2 · registry result, not featured evidence
headache 9.6%
nasopharyngitis 3.8%
back pain 1.9%
NCT03951805 · Phase 2 · registry result, not featured evidence

Notes

  1. aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  2. bPopulation comparability has not been reviewed for both studies.
  3. cTreatment context has not been resolved for both arms.
  4. dPopulation context differs: baseline_threshold differs (bmi<=45, hba1c<=10, hba1c>=7 versus bmi<=40, hba1c<=11, hba1c>=7); prior_therapy differs (experienced versus naive).
  5. eAssessment timepoints differ: 26 weeks versus 52 weeks.
  6. fPopulation comparability has not been reviewed for 25 of these studies.
  7. gPopulation comparability has not been reviewed for 13 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

insulin glargine

MACE 3-point Composite 16.6% (n=6264) vs 16.1% (n=6273) Standard Care
event count · % of participants
Participants with a composite endpoint
NCT00069784 · Phase 3 · converted to % from 1041 participants as posted
Time to CV Death 7.7% (n=6264) vs 7.6% (n=6273) Standard Care
event count · % of participants
Endpoint's composition: CV death
NCT00069784 · Phase 3 · converted to % from 484 participants as posted
Myocardial Infarction 4.7% (n=6264) vs 4.5% (n=6273) Standard Care
event count · % of participants
Endpoint's composition: nonfatal MI
NCT00069784 · Phase 3 · converted to % from 297 participants as posted
show 1 more result
4.1% (n=6264) vs 3.8% (n=6273) Standard Care*
Endpoint's composition: nonfatal MI
NCT00069784 · Phase 3 · converted to % from 257 participants as posted
MACE Broad 28.6% (n=6264) vs 27.5% (n=6273) Standard Care
event count · % of participants
Participants with a composite endpoint
NCT00069784 · Phase 3 · converted to % from 1792 participants as posted
Coronary Revascularization 12.2% (n=6264) vs 11.4% (n=6273) Standard Care
event count · % of participants
Endpoint's composition: revascularization
NCT00069784 · Phase 3 · converted to % from 763 participants as posted
Microvascular Composite 21.1% (n=6264) vs 21.7% (n=6273) Standard Care
event count · % of participants
Participants with a composite endpoint
NCT00069784 · Phase 3 · converted to % from 1323 participants as posted
Albuminuria Progression 18.4% (n=6264) vs 18.7% (n=6273) Standard Care
event count · % of participants
Endpoint's composition: albuminuria progression
NCT00069784 · Phase 3 · converted to % from 1153 participants as posted
Type 2 Diabetes Incidence 24.7% (n=737) vs 31.2% (n=719) Standard Care
event rate · % of participants
NCT00069784 · Phase 3
Time in Range 24 h 26.22 % of time @ 16wk
absolute change · % of time
No placebo or comparator arm
NCT05114590 · Phase 4 · registry result, not featured evidence
Glucose Variability CV 5% (n=113) @ 16wk
absolute change · percentage points
No placebo or comparator arm
NCT05114590 · Phase 4 · registry result, not featured evidence
Daily Plasma Glucose Change mg/dL -2.91 mmol/L @ 16wk
absolute change · mmol/L
No placebo or comparator arm
NCT05114590 · Phase 4 · registry result, not featured evidence · converted to mmol/L from -52.48 mg/dL as posted
PMG Change mg/dL -73.66 mg/dL @ 16wk
absolute change · mg/dL
No placebo or comparator arm
NCT05114590 · Phase 4 · registry result, not featured evidence

+ 57 further endpoints in the CSV export.

insulin icodec

Hypoglycemia Episodes Level 3 0 vs 2 Insulin Degludec count @ 31wk
event count · count
NCT04795531 · Phase 3
show 3 more results
0 vs 0 Insulin Degludec count @ 26wk
NCT04795531 · Phase 3
0 vs 1 Insulin Degludec count @ 31wk
NCT04770532 · Phase 3
7 vs 3 Insulin Glargine count @ 31wk
NCT04880850 · Phase 3
Hypoglycemia Episodes Level 2 53 vs 23 Insulin Degludec count @ 31wk
event count · count
NCT04795531 · Phase 3
show 3 more results
50 vs 17 Insulin Degludec count @ 26wk
NCT04795531 · Phase 3
113 vs 41 Insulin Degludec count @ 31wk
NCT04770532 · Phase 3
937 vs 935 Insulin Glargine count @ 31wk
NCT04880850 · Phase 3
Hypoglycemia Episodes Level 2 or 3 53 vs 25 Insulin Degludec count @ 31wk
event count · count
NCT04795531 · Phase 3
show 3 more results
50 vs 17 Insulin Degludec count @ 26wk
NCT04795531 · Phase 3
113 vs 42 Insulin Degludec count @ 31wk
NCT04770532 · Phase 3
944 vs 938 Insulin Glargine count @ 31wk
NCT04880850 · Phase 3
DTSQs 4.22 vs 2.96 Insulin Degludec score @ 26wk
absolute change · score
NCT04770532 · Phase 3
Time Below 54 mg/dL 0.34% (n=238) vs 0.22% (n=239) Insulin Degludec @ 26wk
absolute value · percentage points
NCT04770532 · Phase 3
Time in Range 66.88 vs 66.44 Insulin Glargine % of time @ 26wk
absolute value · % of time
NCT04880850 · Phase 3
show 5 more results
65.99 vs 64.98 Insulin Glargine U100 % of time @ 16wk
NCT03922750 · Phase 2 · registry result, not featured evidence
72.86 vs 64.98 Insulin Glargine U100 % of time @ 16wk
NCT03922750 · Phase 2 · registry result, not featured evidence
76.65 vs 75.89 Insulin Glargine % of time @ 16wk
NCT03951805 · Phase 2 · registry result, not featured evidence
82.97 vs 75.89 Insulin Glargine % of time @ 16wk
NCT03951805 · Phase 2 · registry result, not featured evidence
80.89 vs 75.89 Insulin Glargine % of time @ 16wk
NCT03951805 · Phase 2 · registry result, not featured evidence
Time Below 54 mg/dL 0.73 vs 0.61 Insulin Glargine % of time @ 26wk
absolute value · % of time
NCT04880850 · Phase 3
SMBG 7-point -1.69 mmol/L @ 52wk
absolute change · mmol/L
No placebo or comparator arm
NCT05813912 · Phase 3 · registry result, not featured evidence · combination
PPG Excursion -1.27 mmol/L @ 52wk
absolute change · mmol/L
No placebo or comparator arm
NCT05813912 · Phase 3 · registry result, not featured evidence · combination
Fasting Plasma Glucose -1.29 mmol/L @ 52wk
absolute change · mmol/L
No placebo or comparator arm
NCT05813912 · Phase 3 · registry result, not featured evidence · combination
SMBG 9-point -2.7 vs -2.26 Insulin Glargine mmol/L @ 26wk
absolute change · mmol/L
NCT03751657 · Phase 2 · registry result, not featured evidence
HbA1c Change mmol/Mol -14.51 vs -12.54 Insulin Glargine mmol/mol @ 26wk
absolute change · mmol/mol
NCT03751657 · Phase 2 · registry result, not featured evidence

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: insulin glargine's landscape · insulin icodec's landscape